Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hongming Pan

Showing results (191-200 of 262) with videos related to

Pageof 27
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2015
BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung CancerCaicun Zhou, Yi-Long Wu, Gongyan Chen, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 27, 2013
Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trialZhihuang Hu, Ying Cheng, Hongyu Zhang, et al.
Future Oncology (London, England)|February 10, 2021
Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib in the FRESCO trialShukui Qin, Jin Li, Yuxian Bai, et al.
BMC Cancer|February 7, 2023
Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II studyChuanliang Cui, Yu Chen, Zhiguo Luo, et al.
British Journal of Cancer|May 11, 2021
Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpressionBaek-Yeol Ryoo, Ann-Li Cheng, Zhenggang Ren, et al.
Clinical and Translational Science|November 29, 2024
Pharmacokinetics of infigratinib and its active metabolites in Chinese patients with advanced gastric cancer harboring FGFR2 gene amplificationJiajia Yuan, Lin Shen, Tian Shu Liu, et al.
Journal for Immunotherapy of Cancer|February 22, 2023
SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancerJun Zhao, Xinmin Yu, Dingzhi Huang, et al.
Plos One|May 23, 2014
Use of metformin alone is not associated with survival outcomes of colorectal cancer cell but AMPK activator AICAR sensitizes anticancer effect of 5-fluorouracil through AMPK activationXinbing Sui, Yinghua Xu, Jie Yang, et al.
Cancer|May 30, 2025
Tebotelimab plus niraparib in previously treated locally advanced or metastatic solid tumors: A phase 1b dose escalation and expansion studyMiao-Zhen Qiu, Hongming Pan, Ka On Lam, et al.
Translational Oncology|April 14, 2019
A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)Lu Si, Xiaoshi Zhang, Yongqian Shu, et al.
Pageof 27

Showing results (191-200 of 262) with videos related to

Sort By:
Pageof 27
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2015
BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung CancerCaicun Zhou, Yi-Long Wu, Gongyan Chen, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 27, 2013
Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trialZhihuang Hu, Ying Cheng, Hongyu Zhang, et al.
Future Oncology (London, England)|February 10, 2021
Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib in the FRESCO trialShukui Qin, Jin Li, Yuxian Bai, et al.
BMC Cancer|February 7, 2023
Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II studyChuanliang Cui, Yu Chen, Zhiguo Luo, et al.
British Journal of Cancer|May 11, 2021
Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpressionBaek-Yeol Ryoo, Ann-Li Cheng, Zhenggang Ren, et al.
Clinical and Translational Science|November 29, 2024
Pharmacokinetics of infigratinib and its active metabolites in Chinese patients with advanced gastric cancer harboring FGFR2 gene amplificationJiajia Yuan, Lin Shen, Tian Shu Liu, et al.
Journal for Immunotherapy of Cancer|February 22, 2023
SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancerJun Zhao, Xinmin Yu, Dingzhi Huang, et al.
Plos One|May 23, 2014
Use of metformin alone is not associated with survival outcomes of colorectal cancer cell but AMPK activator AICAR sensitizes anticancer effect of 5-fluorouracil through AMPK activationXinbing Sui, Yinghua Xu, Jie Yang, et al.
Cancer|May 30, 2025
Tebotelimab plus niraparib in previously treated locally advanced or metastatic solid tumors: A phase 1b dose escalation and expansion studyMiao-Zhen Qiu, Hongming Pan, Ka On Lam, et al.
Translational Oncology|April 14, 2019
A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)Lu Si, Xiaoshi Zhang, Yongqian Shu, et al.
Pageof 27